Kane Biotech Inc. specializes in developing technologies to combat microbial biofilms in the healthcare sector. The company faces significant financial challenges, evident from its low gross margin of 17.7% and extremely negative EBITDA and net margins, indicating operational inefficiencies. Additionally, its current and quick ratios below 1 suggest liquidity concerns. Despite its innovative focus, the low market cap of $6.15M raises questions about investor confidence and valuation, reflecting the need for improved financial health and operational performance.
Loading financial metrics...
Company has $855K in cash but burned $625K last quarter. At this burn rate, only 1.4 quarters of runway remain without additional financing.
Revenue fell 97.3% year-over-year from $1.4M to $39K. The decline has persisted for multiple quarters.
Company posted a loss of $-2.7M over the last year, representing 6980.0% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $2.5M over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q2 (June 30, 2026)